Anzeige
Mehr »
Login
Samstag, 22.01.2022 Börsentäglich über 12.000 News von 667 internationalen Medien
Innocan Pharma: Ist das die beste CBD-Biotech-Aktie nach GW Pharma?!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12BHU ISIN: NL0010872420 Ticker-Symbol: A28 
Tradegate
21.01.22
18:13 Uhr
3,608 Euro
+0,050
+1,41 %
1-Jahres-Chart
AFFIMED NV Chart 1 Jahr
5-Tage-Chart
AFFIMED NV 5-Tage-Chart
RealtimeGeldBriefZeit
3,5223,59421.01.
3,3683,73021.01.

Aktuelle News zur AFFIMED Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
AFFIMED Aktie jetzt für 0€ handeln
06.01.Affimed N.V. - 6-K, Report of foreign issuer11
06.01.Affimed N.V.: Affimed Announces Completion of Enrollment in REDIRECT, the Registration-Directed Study of AFM13 in PTCL, and Provides Business Update11
05.01.Affimed N.V.: Affimed to Present at the 40th Annual J.P. Morgan Healthcare Conference5
13.12.21Affimed N.V.: Affimed Shares Preclinical Data on Innate Cell Engagers AFM28 and AFM13 at the 63rd American Society of Hematology Annual Meeting and Exposition17
09.12.21Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq16
09.12.21Affimed N.V. - 6-K, Report of foreign issuer4
09.12.21Affimed N.V.: Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma Patients with Cord Blood-derived Natural Killer ...3
08.12.21Affimed, Roche commences patient recruitment in Phase 1/2a trial of AFM24 + atezolizumab15
08.12.21Affimed N.V.: Affimed Initiates Patient Recruitment for a Phase 1/2a Trial of Innate Cell Engager AFM24 in Combination with Roche's Anti-PD-L1 Checkpoint ...9
22.11.21Affimed spurs promising response numbers in NK cell study, but durability will be the big question17
22.11.21Affimed's Lymphoma Candidate Shows 100% Objective Response Rate At Highest Dose5
22.11.21Why Affimed Stock Is On Fire Today17
22.11.21Affimed N.V. - 6-K, Report of foreign issuer1
22.11.21Affimed stock jumps 22% after reporting 100% ORR in Phase 1-2 lymphoma study9
22.11.21Affimed N.V.: Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed ...18
12.11.21Affimed N.V.: Affimed Shares Preclinical Data on Mechanism of Action of two Innate Cell Engagers at the 36th SITC Meeting, Demonstrating their Potential ...11
10.11.21Affimed N.V. (AFMD) CEO Adi Hoess on Q3 2021 Results - Earnings Call Transcript6
10.11.21Affimed drops nearly 10% after filing for mixed securities shelf offering17
10.11.21Affimed N.V. - 6-K, Report of foreign issuer7
10.11.21Recap: Affimed Q3 Earnings17
Seite:  Weiter >>
38 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2